trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'bcsm', 'breast']
 #asco22 research: trastuzumab deruxtecan doubles progression-free survival in #metastatic #breastcancer with low her2 expression levels #targetedtherapy #precisionmedicine #cancerresearch #bcsm #patienteducation
Timely, trusted, compassionate doctor-approved info from @ASCO
https://t.co/K04SLVsoar

We cannot answer individual medical questions.

Retweet ?Endorsement